Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 59.2% in September

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 2,000 shares, a decline of 59.2% from the August 31st total of 4,900 shares. Based on an average trading volume of 470,000 shares, the short-interest ratio is currently 0.0 days.

Oncotelic Therapeutics Price Performance

Shares of Oncotelic Therapeutics stock opened at $0.02 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.01 and a current ratio of 0.01. The stock’s 50-day moving average is $0.02 and its 200-day moving average is $0.03. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.05.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.